Overview
Spherix’s coverage of the chronic kidney disease market monitors the dynamic and evolving landscape of CKD non-dialysis patient management. We closely track the competitive hyperkalemia market, along with the rapidly evolving diabetic kidney disease market, with specific deep-dives into SGLT2 inhibitors and their potential seismic market impacts. This research also delves into other disease states impacting CKD non-dialysis patients, such as metabolic acidosis and hypertension.
Follow Spherix Nephrology on Social Media
Follow us for nephrology industry news, insights & analysis:
Twitter: https://twitter.com/SpherixRenal
LinkedIn: https://www.linkedin.com/company/spherix-global-insights/
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com
Services Available
Trending market evolution
-
Chronic Kidney Disease & Diabetic Kidney Disease (US)
-
Hyperkalemia (US)
Exploring the patient journey
-
Chronic Kidney Disease, Non-Dialysis (US)
-
Chronic Kidney Disease, Non-Dialysis – PCP Perspective (US)
-
Chronic Kidney Disease, Non-Dialysis (EU)
-
Dialysis (US)
Prepping for the pipeline
-
Fabry Disease (US)
-
Cross-Specialty Management of CKD & DKD with SGLT2 Inhibitors (US)
BENCHMARKING NEW BRAND PERFORMANCE
-
Kerendia (Bayer) in Diabetic Kidney Disease (US)
-
Korsuva (Vifor) in CKD-associated Pruritus (US)
Gauging impact of disruptive events
-
Feedback from ASN Kidney Week 2022 (US)
-
Fellows and Residents – Nephrology (US)
-
The Business of Nephrology (US)
-
Impact of Inflation and COVID-19 on Specialty Practices – A Cross Specialty Analysis (US)
-
Reactions to FDA Advisory Committees and Decisions*
*Pending results